0 items USD 0.00Search
Your search for "delveinsight chronic heart failure global api manufacturers marketed phase iii drugs landscape 0" gave back 3652 results.
Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their...
iGATE
July 2017
Price: USD 1,250.00
U.S. (United States) pharmaceutical market is the largest pharmaceuticals market in the world and accounted for more than 40% global pharmaceuticals...
Catalog:
NAVADHI
March 2019
Price: USD 3,500.00
With much-awaited approval of biosimilar interchangeability by FDA, the dynamics in the much nascent US biosimilars market is about to change with...
Catalog:
Rockville Research
January 2017
Price: USD 1,200.00
Breast cancer is one of the most fatal cancer witnessed in women and is the second leading cause of death. It refers to cancer developed in breast...
Catalog:
Rockville Research
April 2019
Price: USD 1,100.00
Alcami Corporation - Strategy, SWOT and Corporate Finance Report Summary Alcami Corporation - Strategy, SWOT and Corporate Finance Report, is a...
MarketLine
November 2022
Price: USD 175.00
Achillion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Achillion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate...
MarketLine
February 2020
Price: USD 175.00
The United States market for pain management therapeutics remains a substantial growth area for pharmaceutical companies, as they continue their...
Catalog:
iGATE
September 2017
Price: USD 1,100.00
Cassava Sciences Inc - Strategy, SWOT and Corporate Finance Report Summary Cassava Sciences Inc - Strategy, SWOT and Corporate Finance Report, is a...
MarketLine
January 2023
Price: USD 175.00
Respiratory diseases refers to pathological condition affecting lungs and other parts of the respiratory system. Asthma and COPD are the two most...
Catalog:
Rockville Research
May 2019
Price: USD 1,100.00
Medical holograms have become mainstream technology and has been successfully used by surgeons across the world to improve planning for complex...
Catalog:
Rockville Research
February 2019
Price: USD 900.00
Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report Summary Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report...
MarketLine
February 2022
Price: USD 175.00
Acorda Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Acorda Therapeutics, Inc. - Strategy, SWOT and Corporate Finance...
MarketLine
January 2023
Price: USD 175.00
DaVita Inc. - Strategy, SWOT and Corporate Finance Report Summary DaVita Inc. - Strategy, SWOT and Corporate Finance Report, is a source of...
MarketLine
November 2022
Price: USD 175.00
FDA has recently approved much-awaited first dedicated coronary bifurcated stent for treatment of cardiovascular diseases. The report “Global...
Catalog:
Rockville Research
August 2018
Price: USD 1,500.00
Boston Scientific Corporation - Strategy, SWOT and Corporate Finance Report Summary Boston Scientific Corporation - Strategy, SWOT and Corporate...
MarketLine
November 2022
Price: USD 175.00
